With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Modernization and supply chain diversity drive new growth
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Growth markets revenue increased by 44 YoY to Rs. 812 crore
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
